Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
08/17 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Update Understanding o..
08/17 BRISTOL MYERS SQUIBB : Data from Bristol-Myers Squibb Co. Provide New Insights i..
08/17 BRISTOL MYERS SQUIBB : Patent Issued for ROR.Gamma. Modulators (USPTO 9725443)
08/17 BRAINSTORM CELL THERAPEUTICS : Supports Commitment to ALS Patient Community with..
08/17 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Co. Report Details ..
08/17 BRISTOL MYERS SQUIBB : Research from Bristol-Myers Squibb Co. Yields New Finding..
08/16 Urban Outfitters and Agilent climb; Bristol-Myers skids
08/16 WEDNESDAY’S PIPELINE MOVERS : Bristol-Myers Squibb Company (NYSE:BMY) and ..
08/16 BRISTOL MYERS SQUIBB : Announces Topline Results from CheckMate 214
08/15 BRISTOL MYERS SQUIBB : Announces Topline Results from CheckMate -214, a Phase 3 ..
More news
News from SeekingAlpha
08/18 New Orphan Drug designations in U.S.
08/17 EXELIXIS : Time To Reach The Top
08/16 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 17, 2017
08/16 Bristol-Myers Squibb Combination Treatment Not At The End Of The Crossroad
08/16 Opdivo's Renal Failure Boosts Exelixis - Or Does It?
Financials ($)
Sales 2017 20 493 M
EBIT 2017 5 558 M
Net income 2017 4 624 M
Debt 2017 362 M
Yield 2017 2,80%
P/E ratio 2017 20,37
P/E ratio 2018 18,62
EV / Sales 2017 4,53x
EV / Sales 2018 4,37x
Capitalization 92 525 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,7 $
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-3.46%92 525
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705